Condition

Metastatic Colorectal Cancer (CRC) clinical trials and research

• 19Clinical trials
• 1New in 30 days
• 17Countries

Newest Metastatic Colorectal Cancer (CRC) clinical trials

All recruiting trials (19)

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• HSK42360-Na tablets with cetuximab in BRAF V600-mutant metastatic colorectal cancer

  This Phase 1/2 study tests whether HSK42360-Na tablets with cetuximab, with or without standard chemotherapy, are safe and may help people whose colorectal cancer has a BRAF V600 mutation that has spread.

  Recruiting Phase 1/2 Haisco Pharmaceutical Group Co., Ltd. · Beijing · NCT07790510

• Mindful PaCT: a couple-based mindfulness program for metastatic colorectal cancer

  A couple-focused mindfulness program delivered by video to see if it is practical, acceptable, and helpful for patients with metastatic colorectal cancer and their partners.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT07759921

• Fruquintinib plus anti-EGFR antibody for third-line metastatic colorectal cancer

  This study tests whether adding fruquintinib to cetuximab-beta helps adults with RAS wild-type metastatic colorectal cancer who have already tried and not benefited from at least two prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07724223

• ctDNA-guided anti-EGFR retreatment in metastatic colorectal cancer

  This project will see if using a ctDNA blood test to pick people with metastatic colorectal cancer for anti‑EGFR retreatment leads to better treatment outcomes.

  Recruiting Niguarda Hospital · Milan, Italia · NCT07536113

• Personalized T-cell Therapy iNeo-Vac-T01 for Advanced Colorectal Cancer

  This will test a personalized T-cell therapy called iNeo-Vac-T01 in adults with advanced or metastatic colorectal cancer who have not responded to standard treatments.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07504523

• SAR445877 with FOLFOX6 and bevacizumab as first-line treatment for MSS metastatic colorectal cancer

  This study tests whether giving SAR445877 together with FOLFOX6 and bevacizumab is safe and tolerable as a first-line treatment for adults with MSS metastatic colorectal cancer.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07500298

• Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer

  This phase 2 trial tests whether giving irinotecan with cetuximab again helps patients with metastatic colorectal cancer whose disease progressed after standard therapies, compared with the current standard third-line treatment of trifluridine/tipiracil plus bevacizumab, using blood-based molecular profiling to select

  Recruiting at 19 sites Phase 2 Gruppo Oncologico Italia Meridionale · Alessandria and 25 other locations · NCT07381764

• NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy for first-line metastatic colorectal cancer

  This study tests whether NALIRIFOX combined with a targeted drug works better and is safe compared with FOLFOX plus targeted therapy as the first treatment for adults with inoperable metastatic colorectal cancer.

  Recruiting Phase 3 Shanghai Zhongshan Hospital · Shanghai · NCT07309289

• Ivonescimab versus bevacizumab with FOLFOX for first-line metastatic colorectal cancer

  This study tests whether ivonescimab combined with FOLFOX works as well as bevacizumab with FOLFOX for people starting first-line treatment for metastatic colorectal cancer.

  Recruiting at 243 sites Phase 3 Summit Therapeutics · Mobile, Alabama and 242 other locations · NCT07228832

• Cannabidiol (CBD) to prevent nerve damage from oxaliplatin chemotherapy

  This pilot will test whether hemp-derived cannabidiol (CBD) taken during oxaliplatin chemotherapy can prevent nerve damage in people with metastatic colorectal cancer.

  Recruiting Early Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07167446

• Prognostic Factors for Fruquintinib in Metastatic Colorectal Cancer

  This cohort study tests how clinical and biological factors relate to survival outcomes in adults with metastatic colorectal cancer treated with fruquintinib.

  Recruiting at 83 sites Federation Francophone de Cancerologie Digestive · Poitiers, France and 82 other locations · NCT07124858

• 5‑Fluorouracil–based chemotherapy plus fruquintinib for advanced or metastatic colorectal cancer

  This phase II test will combine 5‑FU–based chemotherapy with the oral drug fruquintinib as a first-line treatment for adults with locally advanced unresectable or metastatic colorectal cancer.

  Recruiting Phase 2 The Methodist Hospital Research Institute · Houston, Texas · NCT07042685

• Combining node-sparing radiotherapy with chemotherapy and immunotherapy for metastatic colorectal cancer

  This study is testing a new treatment that combines a special type of radiation with chemotherapy and immunotherapy to see if it can help people with metastatic colorectal cancer live longer and feel better.

  Recruiting Phase 2/3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT06958419

• BBO-11818 treatment for adults with KRAS mutant cancer

  This study is testing a new drug called BBO-11818 to see if it can help adults with certain types of cancer that have specific KRAS mutations.

  Recruiting at 17 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Los Angeles, California and 16 other locations · NCT06917079

• 5-FU and leucovorin plus regorafenib versus trifluridine‑tipiracil with bevacizumab for third-line metastatic colorectal cancer

  This trial tests whether combining 5-FU and leucovorin with regorafenib works as well as trifluridine‑tipiracil plus bevacizumab for people with metastatic colorectal cancer who have already had two prior lines of treatment.

  Recruiting Phase 2 The Methodist Hospital Research Institute · Houston, Texas · NCT06887218

• Nelmastobart plus trifluridine/tipiracil and bevacizumab for metastatic or recurrent colorectal cancer

  This trial tests whether adding nelmastobart to trifluridine/tipiracil and bevacizumab helps adults with metastatic or recurrent colorectal cancer who cannot use oxaliplatin or irinotecan.

  Recruiting Phase 1/2 STCube, Inc. · Seongnam-si, Gyeonggi-do and 4 other locations · NCT06873763

• Combining TAS-102 and Bevacizumab with Local Treatment for Advanced Colorectal Cancer

  This study is testing a new combination of medications and local treatment for patients with advanced colorectal cancer who didn't get better with their first treatment to see if it works better than the usual second-line therapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06856187

• Combination therapy using HS-20093 for advanced metastatic colorectal cancer

  This study is testing a new combination treatment using HS-20093 for people with advanced metastatic colorectal cancer to see if it is safe and effective, especially for those who haven't had treatment before or who didn't respond to standard therapies.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Hangzhou, Zhejiang · NCT06825624

Related topics

Quick answers

How many Metastatic Colorectal Cancer (CRC) clinical trials are recruiting right now?

19, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 17 countries. The most sites are in China (8 trials), United States (8 trials), Italy (3 trials), France (2 trials), Belgium (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 1: 4, Phase 1/2: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →